Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices – ET HealthWorld


London: medical technology company Zimmer Biomet Holdings beat Wall Street estimates by first quarter profit on Thursday, on the back of robust demand for its devices that are used on the knee and hip reconstruction procedures.

Zimmer results extend a good quarter for medical device manufacturersincluding rival Stryker Corp, which raised its annual profit outlook betting on steady demand for its hip and knee implants.

Investors have higher expectations for medical device manufacturers following a post-pandemic surge in demand for medical procedures, especially among older Americans.

“This is a strong start to the year that should help give investors confidence that management can ultimately deliver on what they set out to do,” JPMorgan analyst Robbie Marcus wrote in a note.

Combined sales of Zimmer’s hip and knee units were $1.28 billion, in line with analyst expectations. The hip and knee implant maker reiterated its annual earnings forecast in the range of $8.00 to $8.15 per share. Analysts had expected full-year earnings of $8.06 per share. Zimmer’s first-quarter revenue rose 3.2 percent to $1.89 billion, compared with analysts’ average estimate of $1.87 billion, according to LSEG data.

On an adjusted basis, the company earned $1.94 per share in the quarter ended March 31, beating estimates of $1.87.

(Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)

    <!–

  • Updated On May 2, 2024 at 05:43 PM IST
  • –>

  • Posted on May 2, 2024 at 05:37 pm IST
  • <!–

  • 1 min read
  • –>

Join the community of over 2 million industry professionals

Subscribe to our newsletter for the latest insights and analysis.

Download the ETHealthworld app

  • Get real-time updates
  • Save your favorite articles


Scan to download the app




Source link

  खाना खाने से पहले जरूर कर लें ये काम, तेजी से गलने लगेगी चर्बी

Leave a Comment